The investigators aim to address the following specific aims:
* Determine the efficacy of Prog in preventing postpartum smoking relapse and reducing smoking relapse risk factors. * Examine the effects of this maternal smoking intervention on infant health. * Examine racial and ethnic differences in intervention outcomes.
Ability to provide informed consent,
Aged 18 to 45 years old
Self-reported stable physical and mental health
self-report uncomplicated pregnancy at gestational week 30 or beyond, or
Current daily use of nicotine replacement therapy or smoking cessation medications, with the exception of e-cigarettes
Current major depressive disorder based on the Patient Health Questionnaire-9 (PHQ-9) and the Beck Depression Inventory
Contraindication to progesterone treatment (e.g., current use of drugs that may inhibit CYP3A4; current or history of deep vein thrombosis, pulmonary embolus, clotting or bleeding disorder, hypertension, stroke, heart disease, or liver dysfunction or disease; or peanut allergy),
Current or within the past 3 months treatment for illicit drug use or alcohol use
Parallel
Progesterone 200 MG Oral Capsule
DrugProgesterone, 200mg, once daily, oral tablet/capsule
Smoking abstinence at Month 6
Child health assessed as smoke exposure and acute infant health.
Click on the lead sponsor to view all of their trials.
University of Minnesota
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
